Taribavirin is an orally active inosine monophosphate dehydrogenase (IMPDH) inhibitor with antiviral activity against multiple viruses, particularly hepatitis C virus (HCV) and influenza virus; it is a prodrug of ribavirin designed to target HCV-infected hepatocytes by concentrating in the liver while minimizing distribution into red blood cells (RBCs) and reducing the risk of hemolytic anemia; it also exhibits cytotoxic effects against MCF-7 breast cancer cells in vitro.